This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Adding a data point of agreement rather than a data point.
Cagrilintide alone would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
I had written a reply contradicting post #92 and deleted it. Here is what survived.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
The variance between people here is larger than the effect being discussed.
I think the cagrilintide alone question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
Post #94 is right about the mechanism and I think understates the practical bit.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
Noting that I have skin in this question and have tried to discount for it.
Coming back to post #96, because the follow-up matters more than the original answer.
Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.
A weak preference rather than a position.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
Post #96 and I disagree about the size of the effect, not about the direction.
On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency alone would suggest. Tolerability is the constraint.
Adding the caveat now so it does not have to be extracted later.
On cagrilintide alone: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Helpful, and easy to find again, which is half of what a good reply is.
Taking post #101 at face value and following it one step further.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
Adding a source would improve this post and I do not have one to hand.
Post #103 and I disagree about the size of the effect, not about the direction.
The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.
Not the answer, but possibly the question that gets there.
The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion implies.
I read post #103 twice before replying, because I had assumed the opposite.
The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.
This has been discussed before and I could not find the thread, so, again.
This follows post #105 rather than contradicting it.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
It is a small point and it changes the answer, which is an awkward combination.
That is clearer than the version I had in my head. Thank you.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…
|
+128 | 142 | 38k | 13mo |
|
Second pass at: Historical amylin analogues and what happened to them
Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. The question about Historical amylin analogues that I actually want…
|
+15 | 19 | 22k | 18mo |
|
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…
|
4 | 19k | 11mo | |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. Proposing that historical amylin analogues deserves a maintained…
|
+29 | 36 | 31k | 1d |
|
The CagriSema phase 2 paper and what a fixed combination buys
Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. Working notes on cagrisema phase 2 paper rather than a…
|
+88 | 93 | 29k | 11mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Comparing tirzepatide and semaglutide is harder than the tables suggest
Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Reading back through what has been written here…
|
2 | 3.8k | 10mo | |
|
What a confidence interval means, from scratch — the long version
The question in the title: What a confidence interval means, from scratch — the long version I will give what I have already checked below so nobody repeats it. Asking about confidence interval directly,…
|
+16 | 20 | 2.3k | 8mo |
|
A 40-week log with the measurement method stated — does this still hold?
A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on 40-week log. It is…
|
+1 | 5 | 14k | 2mo |
|
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about SELECT in a thread…
|
2 | 1.9k | 5mo | |
|
[2026 update] Journal club: what we got wrong in an earlier session
Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. Bringing a claim rather than a paper, because the claim is the thing circulating.…
|
+5 | 9 | 4.2k | 1d |